Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion

Inclusion Criteria: * Age \>19 years * Child-Pugh class A liver function * Performance status: Eastern Cooperative Oncology Group (ECOG) score 0 or 1 * Hepatocellular carcinoma (HCC) confirmed by dynamic CT or MRI, or by biopsy * HCC invasion of first or second branch portal vein or hepatic vein or inferior vena cava * Reserved unilateral portal blood flow at least in partial * HCC size larger than 1 cm and less than 50% of total liver volume * No confirmed extrahepatic metastasis * Adequate hematopoietic function Hemoglobin ≥ 8.5 g/dL Absolute neutrophil count ≥ 750/mm3 Platelet count ≥ 30,000/mm3 * Creatinine \< 1.5mg/dL * No plan for pregnancy or breast feeding. Active contraception. * Willing to give informed consent Exclusion Criteria: * Prior history to or exposure of transarterial chemoembolization, external beam radiation to liver, or sorafenib * Complete obstruction of hepatic outflow * Confirmed extrahepatic metastasis of HCC * HCC occupying more than 50% of liver volume * Uncontrolled ascites of hepatic encephalopathy * Prior liver transplantation * Positive for human immunodeficiency virus (HIV) * Active gastric or duodenal ulcer * Other uncontrolled comorbidities or malignancy * Inability to give informed consent